Suppr超能文献

HPV 初筛检测:美国女性对新兴筛查方式的认知和接受度。

Primary HPV testing: U.S. women's awareness and acceptance of an emerging screening modality.

机构信息

Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States.

Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States.

出版信息

Prev Med. 2018 Mar;108:111-114. doi: 10.1016/j.ypmed.2017.12.007. Epub 2017 Dec 23.

Abstract

BACKGROUND

Primary HPV testing (without the Pap test) has recently been recommended as a cervical cancer screening option in the United States. U.S. women's awareness and acceptance of primary HPV testing were evaluated.

METHODS

Data from a 2015 web-based survey of U.S. adults was examined. Analyses were limited to women who were ≥18years old, had not undergone a hysterectomy, had not been diagnosed with cervical cancer, and would accept cervical cancer screening (N=1309). Logistic regression was used to identify predictors of acceptance of primary HPV testing every 3years.

RESULTS

Primary HPV testing every 3years was the least accepted cervical cancer screening option (13.5%), and annual Pap testing was the most accepted (41.2%). Most women (65.2%) reported that they were unsure how the HPV test is administered. HPV-vaccinated women were more likely to accept primary HPV testing every 3years than unvaccinated women (Adj OR=1.80, 95% CI=1.22-2.63, p=0.003). And, women who had participated in HPV testing at any interval were more likely to accept primary HPV testing every 3years than those who did not have regular HPV tests or were unsure how often they had HPV tests (Adj OR=1.74, 95% CI=1.20-2.52, p=0.003).

CONCLUSIONS

Acceptance of primary HPV testing among U.S. women was low and associated with variables which may be indicative of general HPV awareness. Widespread adoption of primary HPV testing may require increasing women's familiarity with the HPV test and screening guidelines.

摘要

背景

原发性 HPV 检测(不包括巴氏涂片检查)最近在美国被推荐作为宫颈癌筛查的一种选择。评估了美国女性对原发性 HPV 检测的认识和接受程度。

方法

对 2015 年美国成年人的一项基于网络的调查数据进行了分析。分析仅限于年龄在 18 岁及以上、未行子宫切除术、未被诊断为宫颈癌且愿意接受宫颈癌筛查的女性(N=1309)。使用逻辑回归确定了每 3 年接受一次原发性 HPV 检测的接受程度的预测因素。

结果

每 3 年进行一次原发性 HPV 检测是最不受欢迎的宫颈癌筛查方法(13.5%),而每年进行一次巴氏涂片检查是最受欢迎的方法(41.2%)。大多数女性(65.2%)报告称,她们不确定 HPV 检测是如何进行的。接种 HPV 疫苗的女性比未接种疫苗的女性更有可能每 3 年接受一次原发性 HPV 检测(调整后的优势比[OR]=1.80,95%置信区间[CI]=1.22-2.63,p=0.003)。而且,在任何时间间隔内参加过 HPV 检测的女性比没有定期进行 HPV 检测或不确定自己多久进行一次 HPV 检测的女性更有可能每 3 年接受一次原发性 HPV 检测(调整后的 OR=1.74,95% CI=1.20-2.52,p=0.003)。

结论

美国女性对原发性 HPV 检测的接受程度较低,且与可能表明 HPV 总体认知的变量相关。广泛采用原发性 HPV 检测可能需要增加女性对 HPV 检测和筛查指南的熟悉程度。

相似文献

1
Primary HPV testing: U.S. women's awareness and acceptance of an emerging screening modality.
Prev Med. 2018 Mar;108:111-114. doi: 10.1016/j.ypmed.2017.12.007. Epub 2017 Dec 23.
2
Acceptable and Preferred Cervical Cancer Screening Intervals Among U.S. Women.
Am J Prev Med. 2015 Dec;49(6):e99-107. doi: 10.1016/j.amepre.2015.04.025. Epub 2015 Jul 2.
3
Primary Human Papillomavirus Screening: Women's Perceptions of New Cervical Cancer Screening Recommendations.
J Womens Health (Larchmt). 2024 Dec;33(12):1614-1624. doi: 10.1089/jwh.2023.1180. Epub 2024 Sep 11.
4
Recent changes in cervical cancer screening guidelines: U.S. women's willingness for HPV testing instead of Pap testing.
Prev Med. 2020 Jan;130:105928. doi: 10.1016/j.ypmed.2019.105928. Epub 2019 Nov 19.
5
National assessment of HPV and Pap tests: Changes in cervical cancer screening, National Health Interview Survey.
Prev Med. 2017 Jul;100:243-247. doi: 10.1016/j.ypmed.2017.05.004. Epub 2017 May 11.
7
Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
J Womens Health (Larchmt). 2019 Aug;28(8):1094-1104. doi: 10.1089/jwh.2018.7141. Epub 2019 Mar 15.
10
Primary HPV testing recommendations of US providers, 2015.
Prev Med. 2017 Dec;105:372-377. doi: 10.1016/j.ypmed.2017.08.006.

引用本文的文献

3
Primary HPV screening compared with other cervical cancer screening strategies in women with HIV: a cost-effectiveness study.
AIDS. 2024 Dec 1;38(15):2030-2039. doi: 10.1097/QAD.0000000000004002. Epub 2024 Aug 30.
5
Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California.
Cancer Epidemiol Biomarkers Prev. 2023 Jan 9;32(1):91-97. doi: 10.1158/1055-9965.EPI-22-0793.
6
Women's attitudes towards a human papillomavirus-based cervical cancer screening strategy: a systematic review.
BMJ Sex Reprod Health. 2022 Oct;48(4):295-306. doi: 10.1136/bmjsrh-2022-201515. Epub 2022 Aug 5.
7
Changing Preferences for a Cervical Cancer Screening Strategy: Moving Away from Annual Testing.
Womens Health Rep (New Rochelle). 2022 Aug 4;3(1):709-717. doi: 10.1089/whr.2022.0007. eCollection 2022.
8
Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
Gynecol Oncol. 2021 Nov;163(2):378-384. doi: 10.1016/j.ygyno.2021.08.023. Epub 2021 Sep 8.

本文引用的文献

1
Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial.
Pediatrics. 2017 Jan;139(1). doi: 10.1542/peds.2016-1764. Epub 2016 Dec 5.
2
Practice Bulletin No. 157: Cervical Cancer Screening and Prevention.
Obstet Gynecol. 2016 Jan;127(1):e1-e20. doi: 10.1097/AOG.0000000000001263.
3
Understanding the role of the news media in HPV vaccine uptake in the United States: Synthesis and commentary.
Hum Vaccin Immunother. 2016 Jun 2;12(6):1430-4. doi: 10.1080/21645515.2015.1109169. Epub 2015 Nov 10.
4
Acceptable and Preferred Cervical Cancer Screening Intervals Among U.S. Women.
Am J Prev Med. 2015 Dec;49(6):e99-107. doi: 10.1016/j.amepre.2015.04.025. Epub 2015 Jul 2.
6
Intervention effects from a social marketing campaign to promote HPV vaccination in preteen boys.
Vaccine. 2014 Jul 16;32(33):4171-8. doi: 10.1016/j.vaccine.2014.05.044. Epub 2014 Jun 2.
7
Educational interventions to increase HPV vaccination acceptance: a systematic review.
Vaccine. 2014 Apr 7;32(17):1901-20. doi: 10.1016/j.vaccine.2014.01.091. Epub 2014 Feb 14.
8
Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.
Lancet. 2014 Feb 8;383(9916):524-32. doi: 10.1016/S0140-6736(13)62218-7. Epub 2013 Nov 3.
9
Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.
Ann Intern Med. 2012 Jun 19;156(12):880-91, W312. doi: 10.7326/0003-4819-156-12-201206190-00424.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验